

School of Medicine
Department of Haematology
Professor A K Burnett
Ysgol Meddygaeth
Adran Hematoleg
Yr Athro A K Burnett



Cardiff University
Heath Park
Cardiff CF14 4XN
Tel Ffôn +44(0)29 2074 2375
Fax Ffacs +44(0)29 2074 4655
E-mail E-bost
BurnettAK@cardiff.ac.uk
Prifysgol Caerdydd
Mynydd Bychan
Caerdydd CF14 4XN

21st July 2009

Dr Corinne Scott
Committee Co-ordinator
MREC for Wales
Churchill House
Fourth Floor
17 Churchill Way
CARDIFF
CF10 2TW

Dear Dr Scott

**Re: AML17: A Programme of Treatment Development for Younger Patients
with Acute Myeloid Leukaemia and High Risk Myelodysplastic
Syndrome
Eudract No: 2007-003798-16
ISRCTN55675535**

Thank you for communicating the committee's recent position. I can confirm that patients who fail the CEP701 randomisation will be regarded as high risk and therefore will be eligible to enter the high risk part of the protocol which leads to stem cell transplantation. This will include treatment with AraC Daunorubicin or Clofarabine Daunorubicin.

Thank you for your assistance.

Yours sincerely

Professor Alan K Burnett